Cargando…
Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents
Dipeptidyl peptidase-IV (DPP-IV) inhibitors, often known as gliptins, have been used to treat type 2 diabetes mellitus (T2DM). They may be combined with other medications as an additional treatment or used alone as a monotherapy. In addition to insulin, sulfonylureas, thiazolidinediones, and metform...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502781/ https://www.ncbi.nlm.nih.gov/pubmed/36144735 http://dx.doi.org/10.3390/molecules27186001 |
_version_ | 1784795790331346944 |
---|---|
author | Mohammad, Badrud Duza Baig, Mirza Shahed Bhandari, Neeraj Siddiqui, Falak A. Khan, Sharuk L. Ahmad, Zubair Khan, Farhat S. Tagde, Priti Jeandet, Philippe |
author_facet | Mohammad, Badrud Duza Baig, Mirza Shahed Bhandari, Neeraj Siddiqui, Falak A. Khan, Sharuk L. Ahmad, Zubair Khan, Farhat S. Tagde, Priti Jeandet, Philippe |
author_sort | Mohammad, Badrud Duza |
collection | PubMed |
description | Dipeptidyl peptidase-IV (DPP-IV) inhibitors, often known as gliptins, have been used to treat type 2 diabetes mellitus (T2DM). They may be combined with other medications as an additional treatment or used alone as a monotherapy. In addition to insulin, sulfonylureas, thiazolidinediones, and metformin, these molecules appear as possible therapeutic options. Oxadiazole rings have been employed in numerous different ways during drug development efforts. It has been shown that including them in the pharmacophore increases the amount of ligand that may be bound. The exceptional hydrogen bond acceptor properties of oxadiazoles and the distinct hydrocarbon bonding potential of their regioisomers have been established. Beside their anti-diabetic effects, oxadiazoles display a wide range of pharmacological properties. In this study, we made the assumption that molecules containing oxadiazole rings may afford a different approach to the treatment of diabetes, not only for controlling glycemic levels but also for preventing atherosclerosis progression and other complications associated with diabetes. It was observed that oxadiazole fusion with benzothiazole, 5-(2,5,2-trifluoroethoxy) phenyl, β-homophenylalanine, 2-methyl-2-{5-(4-chlorophenyl), diamine-bridged bis-coumarinyl, 5-aryl-2-(6′-nitrobenzofuran-2′-yl), nitrobenzofuran, and/or oxindole leads to potential anti-diabetic activity. |
format | Online Article Text |
id | pubmed-9502781 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95027812022-09-24 Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents Mohammad, Badrud Duza Baig, Mirza Shahed Bhandari, Neeraj Siddiqui, Falak A. Khan, Sharuk L. Ahmad, Zubair Khan, Farhat S. Tagde, Priti Jeandet, Philippe Molecules Review Dipeptidyl peptidase-IV (DPP-IV) inhibitors, often known as gliptins, have been used to treat type 2 diabetes mellitus (T2DM). They may be combined with other medications as an additional treatment or used alone as a monotherapy. In addition to insulin, sulfonylureas, thiazolidinediones, and metformin, these molecules appear as possible therapeutic options. Oxadiazole rings have been employed in numerous different ways during drug development efforts. It has been shown that including them in the pharmacophore increases the amount of ligand that may be bound. The exceptional hydrogen bond acceptor properties of oxadiazoles and the distinct hydrocarbon bonding potential of their regioisomers have been established. Beside their anti-diabetic effects, oxadiazoles display a wide range of pharmacological properties. In this study, we made the assumption that molecules containing oxadiazole rings may afford a different approach to the treatment of diabetes, not only for controlling glycemic levels but also for preventing atherosclerosis progression and other complications associated with diabetes. It was observed that oxadiazole fusion with benzothiazole, 5-(2,5,2-trifluoroethoxy) phenyl, β-homophenylalanine, 2-methyl-2-{5-(4-chlorophenyl), diamine-bridged bis-coumarinyl, 5-aryl-2-(6′-nitrobenzofuran-2′-yl), nitrobenzofuran, and/or oxindole leads to potential anti-diabetic activity. MDPI 2022-09-15 /pmc/articles/PMC9502781/ /pubmed/36144735 http://dx.doi.org/10.3390/molecules27186001 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Mohammad, Badrud Duza Baig, Mirza Shahed Bhandari, Neeraj Siddiqui, Falak A. Khan, Sharuk L. Ahmad, Zubair Khan, Farhat S. Tagde, Priti Jeandet, Philippe Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents |
title | Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents |
title_full | Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents |
title_fullStr | Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents |
title_full_unstemmed | Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents |
title_short | Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents |
title_sort | heterocyclic compounds as dipeptidyl peptidase-iv inhibitors with special emphasis on oxadiazoles as potent anti-diabetic agents |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502781/ https://www.ncbi.nlm.nih.gov/pubmed/36144735 http://dx.doi.org/10.3390/molecules27186001 |
work_keys_str_mv | AT mohammadbadrudduza heterocycliccompoundsasdipeptidylpeptidaseivinhibitorswithspecialemphasisonoxadiazolesaspotentantidiabeticagents AT baigmirzashahed heterocycliccompoundsasdipeptidylpeptidaseivinhibitorswithspecialemphasisonoxadiazolesaspotentantidiabeticagents AT bhandarineeraj heterocycliccompoundsasdipeptidylpeptidaseivinhibitorswithspecialemphasisonoxadiazolesaspotentantidiabeticagents AT siddiquifalaka heterocycliccompoundsasdipeptidylpeptidaseivinhibitorswithspecialemphasisonoxadiazolesaspotentantidiabeticagents AT khansharukl heterocycliccompoundsasdipeptidylpeptidaseivinhibitorswithspecialemphasisonoxadiazolesaspotentantidiabeticagents AT ahmadzubair heterocycliccompoundsasdipeptidylpeptidaseivinhibitorswithspecialemphasisonoxadiazolesaspotentantidiabeticagents AT khanfarhats heterocycliccompoundsasdipeptidylpeptidaseivinhibitorswithspecialemphasisonoxadiazolesaspotentantidiabeticagents AT tagdepriti heterocycliccompoundsasdipeptidylpeptidaseivinhibitorswithspecialemphasisonoxadiazolesaspotentantidiabeticagents AT jeandetphilippe heterocycliccompoundsasdipeptidylpeptidaseivinhibitorswithspecialemphasisonoxadiazolesaspotentantidiabeticagents |